18th Annual European Life Sciences CEO Forum

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.

Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations.

Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Sweden.

ANOC-001 is the first product to enter human trials from Anocca’s robust T-cell receptor T-cell therapy (TCR-T) pipeline and, subject to approval, the trial will start during Q2, 2025.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

MitoRx Therapeutics (UK) is developing a first-in-class small-molecule weight loss therapy addressing the key unmet need in a GLP-1 dominated obesity market: targeted fat loss with preservation of lean mass and preservation of muscle function, a TPP that is clearly differentiated from standard-of-care GLP-1 drugs.

SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science Enterprises (OSE) and Google Ventures (GV). The company raised $32.5 million in a Series A equity financing in 2021. Based on science developed at the University of Oxford, SpyBiotech’s novel vaccine platform is based on a proprietary protein “superglue” technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related “superglue” technologies in vaccine development.

XYone Therapeutics was established in 2021 to translate innovative discoveries spun out of Dana Farber Cancer Center/Harvard Univ. and Boston Univ. Based in a Boston Suburb, XYone is developing First-In-Class ADCs targeting tumor-anchored Mucin 1 (MUC1-C).

XYone has raised $17.5 million and received several, multimillion-dollar, non-dilutive innovation grants from NIH. Now we are initiating a $38 million Series A round to accelerate clinical development of the ADC oncology pipeline​​.
--
Two MUC1-C targeting ADCs in advanced stages of development:

XYA01 (MMAE payload ADC): Awarded acceptance into the NCI NExT program of the National Cancer Institute (NIH, US). NCI will generate all the IND enabling data, GMP production, and IND filing with the FDA; XYone retains all the rights on the drug. Non-dilutive contribution of ~$12-15MM USD. IND planned for early 2026.

XYA02 (Exatecan payload ADC): GMP development initiated, IND planned for Q2, 2026.
--
mAbs licensed to Posieda/Roche for CAR-cell therapies: entitled to ~$71MM milestones + royalties.

Compelling pipeline of T-Cell engager, and multispecific anti-tumor therapeutics.

We are a clinical Phase I/II biotech company focused on the development of a platform technology for cellular and biologic therapies to treat overshooting T cell mediated autoimmune and autoinflammatory diseases with high medical unmet needs.

Our cell therapeutic approach is unique being ready to use within 24 hrs (ultrafast manufacturing process), is very cost efficient and IP protected.

With our lead cellular product, Actileucel (activated regulatory T cells), our goal is to prevent GvHD at an early stage and to provide a curative therapy with few side effects for patients undergoing blood stem cell transplantation for the first time. Actileucel is a safe and efficient treatment option that addresses a significant unmet medical need. First patients have been treated with a very good safety profile.

Actileucel has the potential to overcome current risks and limitations inherent in stem cell transplantation.

In addition, due to our platform technology Actileucel has a very high upside potential.

AVEROA PHARMA is an emerging innovative company, based in France focused on the development and registration of drugs with high interest to patients with kidney or metabolic diseases.

The company has a pipeline of highly innovative products, some of them in early research and development ensuring a high potential valuation at exit and others that require very limited investment but contribute significantly to the financing of the pipeline while avoiding dilution to our future investors.
AVEROA PHARMA is a company with clinical stage assets, Xoanacyl® is currently in the European registration process with an expected launch in Q1 2026, while AVA2171, addressing a rare kidney disease, should be in the registration phase in 2026/2027. AVA2206, a compound about to enter Phase I clinical trials, has the potential to target multiple rare diseases and could be accompanied by a medical device (AVA2065) to aid in the diagnosis and monitoring of those diseases.

The company employees are experts in clinical development, regulatory management, strategy and market access.

The company is looking to raise funding.

Clinical Phase 1 & 2 company developing therapeutics to target tumor hypoxia to overcome cancer treatment resistance and 2x immunotherapy efficacy.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Sanofi, Incyte, Adimab and LG Chem.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

Lead Pharma is a leading pharmaceutical Research & Development company discovering, designing, and developing innovative small-molecule therapies in three therapeutic areas:
1) Immunology
2) Oncology
3) Metabolic disease.

A clinical-stage company with strong capabilities and unparalleled expertise in the discovery and optimization of novel chemotypes developing a differentiated pipeline with first-in-class and best-in-class projects.

We would like to meet with Pharma companies to explore partnering opportunities and with VCs to explore strategic investment opportunities.

LightOx, headquartered in the UK, is at the forefront of developing innovative light-activated therapies, with a primary focus on treating early-stage oral cancers. Their lead candidate, LXD191, is a novel photosensitizing agent designed for topical application to pre-cancerous lesions in the oral cavity. Upon activation by a specific wavelength of light, LXD191 induces targeted cell death eliminating cancerous tissues while minimising damage to surrounding healthy cells.

This process involves a clinician applying a gel containing LXD191 directly to the affected area. The drug is activated using a simple light offering a less invasive alternative to traditional surgical procedures, aiming to reduce patient discomfort and improve recovery times.

Pre-clinical studies have demonstrated promising results, with LXD191 showing significant efficacy in inducing cell death in cancerous tissues upon light activation. Building on these findings, LightOx has collaborated with the clinical team at the Liverpool Head and Neck Centre and formulation specialists to develop a suitable gel for clinical use.

In recognition of their groundbreaking work, LightOx has won multiple non dilutive grants from the UK. This funding supports the advancement of LXD191 through final pre-clinical phases and facilitates collaboration with clinical partners to develop a “chair-side” treatment for patients with early-stage oral cancers.

LightOx will raise £10M in a Series A round to initiate Phase I/IIa clinical trials for LXD191 in 2026, aiming to provide a minimally invasive treatment option for patients with oral dysplasia and reduce their risk of developing mouth cancer. The company’s innovative approach has the potential to transform the management of early-stage oral cancers, offering a convenient and effective alternative to surgery.

LightOx second asset is a light-activated antimicrobial gel specifically designed to treat chronic wounds. LXD231, has shown to be active against the WHO, ESKAPE pathogens.

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.

NEC Bio B.V. under the umbrella of NEC Corporation-a notable ICT conglomerate in Japan is a clinical stage biotech company focused on the development of artificial intelligence driven therapies within immuno-oncology and infectious disease vaccines. Our personalized neoantigen cancer vaccines are currently being investigated in the clinic with promising preliminary data published at AACR 2024. We have also developed a proprietary BCE hunt technology for Ab discovery.

PhoreMost is a Cambridge UK-based biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. The company has a number of disclosed alliances with partners, including Roche and Boehringer Ingelheim.

PMC-001 | Phase-1 ready asset positioned for solid tumours including brain metastasis.

PMC-002 | Novel synthetic lethal target for treatment of HPV+ cancers

PMC-003 | Degrader driven by novel ligase to overcome limitations of pan-BRD4i

TPD Platform | ‘Beyond Cereblon’ chemical ligase platform(s) for protein-of-interest degradation and pipeline expansion.

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues. The technology is based on natural plant endosomal escape enhancers that are conjugated to any large molecule of interest and targeting ligands such as GalNAc and antibodies for cell- and tissue-specific delivery.

We have successfully translated the technology in non-human primates and have in vivo PoCs in muscle, heart, kidney and tumor tissue. Sapreme is now building a pipeline, and our lead candidate is designed to become best-in-class for Duchenne by using a transferrin receptor 1-antibody coupled to our endosomal escape enhancer to enable intracellular delivery of the RNA exon-skipping payload.

The company is now raising a €50 M Series A to develop our own pipeline beyond clinical translation in 2027. We are also pursuing strategic partnerships on our technology to co-develop products with select pharma/biotech companies and recently signed our first option deal, for an exclusive license on our technology to enable RNA therapeutics in kidney.

Sarcura, an Austrian deep-tech startup, is pioneering the development of CellFAB—a miniaturized, autonomous manufacturing platform designed to execute all unit operations within a closed cartridge.

By leveraging cutting-edge silicon chip technology, we seamlessly integrate real-time analytics to enable the precise selection of highly specific cell populations within a compact footprint.
Our advanced analytical capabilities generate process insights, empowering AI and machine learning to precisely control complex living therapies—eliminating the need for human intervention.
This approach ensures true scalability, making affordable, mass-customized cell therapies a reality.

Spago Nanomedical is a Swedish clinical stage company focusing on development of novel radiopharmaceuticals for expanded treatment of multiple solid tumor indications.

SpikImm is a spin off from Insitut Pasteur, and has access to its research capabilities. The company is focussed on Long acting mAbs to give immunocompromised patients passive immunity (that normally vaccines provide).

Our lead program is aimed at protecting Kidney Transplant & HCST patients from BK virus and is also applicable to patiemnts at risk of JC virus (which is lethal).

We are run by a highly experienced (and older) team of experts, in a virtual manner.

Funding to date by Truffle Capital, but now undertaking a significant raise with Stragetic & VC investors at termsheet stage.

STIMIT is revolutionizing respiratory & critical care: we use neurostimulation to empower patients to breathe. STIMIT discovered a greenfield beyond heart and brain neurostimulation: lung-related neurostimulation is the new breakthrough in this field.

A healthy person breathes 20,000 times a day, while ventilated patients in the intensive care unit frequently do not breathe at all (passive ventilation instead of active breathing). The central respiratory muscle, the diaphragm, is lost in these patients by up to 50% in the first 3 days, resulting in prolonged ventilation and ICU complications. This is a multi-billion dollar market on each continent, STIMIT has a validated value-based business model.
Diaphragm neurostimulation is important for lung health, for brain function, and venous backflow to the heart.

Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Engineered Phage Lytic Proteins as new antimicrobial products.

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as systemic cytotoxic therapies and radiotherapy induced mucositis, dermatitis, and hair-loss.

We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a platform of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during their journey of cancer treatments.

ViaNautis Bio develops genetic medicines for CNS diseases, including epilepsy, Frontotemporal Dementia (FTD), and Parkinson’s, using proprietary PolyNaut® nanovesicles (PNVs). PNVs enable efficient delivery of DNA, ASO, and mRNA to the brain with high specificity, leveraging ligand-based targeting. We have demonstrated BBB crossing with angiopep2 PNVs, effectively targeting neurons and astrocytes without activating microglia. Compared to AAV and LNPs, PNVs offer re-dosing potential, 4°C stability, scalability, and large cargo capacity. ViaNautis is backed by leading investors, including 4BIO, BGF, UCBV, Lilly Ventures, and CFF, and has entered a multi-year, multi-target partnership with Eli Lilly to advance novel genetic medicines.

Alpioner Therapeutics is a biotech company developing a new generation of vaccine candidates to fight against cancer and multi-resistant pathogens. Alpioner's proprietary bacterial platform leverages an inducible secretion system acting as a “microsyringe”, i.e. a potent antigen/functional protein delivery vectors capable of injecting efficiently and in high dose directly into the host cell cytosol.

Based on this platform, Alpioner Tx is developing a personalized therapeutic cancer vaccine which includes selected neoantigens and a first-in-class live attenuated vaccine candidate against Pseudomonas aeruginosa.
Alpioner’s mission is to save lives of patients suffering from difficult-to-treat cancers and from multi-resistant bacterial pathogens infections by developing highly immunogenic and strongly protective vaccine candidates.

Potent antigen/functional protein delivery vectors.

brainQr Therapeutics is a pioneering biotechnology company redefining the treatment of devastating human diseases by targeting the dynamic proteome—disordered proteins that were long considered undruggable.

Core Technology:
brainQr leverages its cutting-edge AI-IDP platform to accelerate the discovery and development of groundbreaking therapies. By combining experimental precision with AI-driven innovation, brainQr unlocks therapeutic potential in areas previously unreachable.

Lead Program:
brainQr's flagship program focuses on stabilizing the native structure of the Tau protein by small molecules to combat Alzheimer’s disease. This first-in-class approach addresses the root cause of neurodegeneration by halting pathological aggregation and spreading of Tau.

Broader Impact:
The company’s innovative platform extends beyond Alzheimer’s disease, with applications across neurodegeneration, oncology, and rare diseases. brainQr is committed to transforming healthcare by addressing critical unmet medical needs globally.

HHC is developing first-in-class nucleic acid-based therapies (NATs) for anything from head and neck cancer to the future promise of curing Parkinson's disease. Our platform technology enables highly localized in vivo drug uptake with wireless electroporation. By using focused electromagnetic waves to manipulate the membrane of cells at a target site in the patient’s body, HHC enables a precise and highly localized drug uptake, while avoiding systemic side effects.

MicThera is a pioneering biotech startup developing microbial-inspired therapeutics to tackle resistance in prostate cancer and infectious diseases.
In oncology, our lead program targets prostate cancer resistance pathways, backed by preclinical in-vivo efficacy data, addressing the urgent need for effective therapies in treatment-resistant disease forms. The efficacy of our oncology asset has been validated in other cancer types beyond prostate.
In infectious diseases, we focus on novel antimicrobial peptides with potent activity against drug-resistant pathogens, with in vitro efficacy demonstrated. With the rise of antimicrobial resistance, our innovative approach offers promising solutions for combating life-threatening infections.

With exclusive licensing rights to patented technologies, proprietary patents, a founding team composed of world-leader scientists in prostate cancer and microbiota, we are positioned to advance products developed through a novel concept of targeting diseases by harnessing bacteria power.

Our proprietary discovery platform identifies and optimizes bioactive peptides from microbes, enabling the development of first-in-class treatments with novel mechanisms of action. The platform integrates AI-driven peptide mining and screening, cutting-edge research, and advanced screening to generate highly specific and effective therapeutics. This unique approach allows us to unlock the untapped potential of microbial peptides, offering a scalable pipeline of transformative treatments.

MicThera is actively seeking strategic partnerships to accelerate development, expand our pipeline, and bring our novel therapies to patients worldwide. We welcome collaborations with biopharma companies, investors, and research organizations to advance the next generation of microbial-inspired medicines.

Panntherapi is a clinical stage biotech company developing innovative drugs in Neurology by acting on a new specific target only involved in pathological processes. Our first in class clinical stage product (Phase 1 done, ready for phase 2) is indicated to treat a dramatic resistant epileptic syndrome mostly pediatric (2 patents + Orphan drug status). With our unique platform (AI, in vitro and ex vivo models using postoperative tissues from patients), we also identified new chemicals entities (1 patent) which will develop in other diseases of interest such as multiple sclerosis, pain, psychiatry or neurodegenerative diseases.

Laureate of the EIC Accelerator (grant + equity) among others, Panntherapi is a French company with a highly skilled team coming from pharma and biotech industries. We are looking for a seed funding to perform the proof of concept clinical trial in the orphan epileptic syndrome, and pursue the characterization of our other compounds. We already received expression of interest from 5 pharmaceutical companies (CDA signed) for a potential licensing of our compounds after the obtention of clinical data, validating the first candidate, the target and our platform.

Scarlet's mission is to pioneer the use of universal red blood cells, unmodified or modified, for the benefit of human health. The platform is applicable to blood transfusion indications and for the treatment of many diseases, including metabolic diseases, autoimmune conditions and cancer. The initial focus for clinical proof of concept for our platform is the treatment of a number of metabolic diseases with high clinical unmet needs.

Vectiopep: Unlocking T-Cell Potency via Precision mRNA Delivery

Vectiopep is a preclinical-stage biotech pioneering a next-generation mRNA delivery platform designed to overcome the "liver-sink" limitations of current technologies. Our mission is to transform the treatment landscape for cold tumors, specifically Micro-satellite Stable Colorectal Cancer (MSS CRC), where standard immunotherapies often fail.

The Technology:
- Leveraging our proprietary, patented peptide-based mRNA vector, Vectiopep enables a fundamental shift in biodistribution. We achieve >99% selective delivery to the lymphoid organs, with negligible off-target liver accumulation.
- This precision triggers an unprecedented immune response, driving 10x stronger antigen-specific T-cell activation than industry-standard lipid nanoparticle (LNP) benchmarks, significantly widening the therapeutic window.

Pipeline & Status:
While our lead program focuses on MSS CRC, our platform’s superior biodistribution has broad-spectrum applicability, including in vivo CAR-T and high-potency preventive vaccination for complex pathogens. With our core patent granted and €1.2M in recent funding, we have finalized Lead Candidate selection and are now advancing toward Lead Compound selection in H2 2026.